Colorectal Cancer
TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
| Status | Conditions | Phase | Study ID |
| Recruiting | Colorectal Cancer | Phase III |
7627 NCT01483027 |
Summary
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
|
|
Eligibility Criteria (must meet the following to participate in this study)
Inclusion Criteria:
- Colorectal cancer with metastases progressed after first line treatment
Exclusion Criteria:
- Contraindications to TheraSphere or second line chemotherapy
Exclusions (conditions that would prevent participation in this study)
Last Updated
March 14, 2013See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
Join Us On